Zymeworks Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Zymeworks (Nasdaq: ZYME) announced that management will participate in investor conferences in November 2025. Key appearances include one-on-one meetings at the Stifel Healthcare Conference on November 11, 2025 in New York, and one-on-one meetings at the Jefferies London Healthcare Conference on November 17–19, 2025 in London.

The company is a clinical-stage biotechnology firm developing multifunctional biotherapeutics for oncology, inflammation, and autoimmune diseases; these investor meetings are opportunities to discuss clinical progress and corporate strategy with investors and analysts.

News Market Reaction

+4.49%

1 alert

+4.49% News Effect

On the day this news was published, ZYME gained 4.49%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:

• Stifel Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 11, 2025, in New York, NY.
• Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 17- 19, 2025, in London, UK.
  
  

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. A Phase 1 study for ZW191 is actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Investor inquiries:

Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

FAQ

When will Zymeworks (ZYME) present at the Stifel Healthcare Conference?

Zymeworks management will participate in one-on-one meetings on November 11, 2025 in New York.

What are Zymeworks' (ZYME) dates at the Jefferies London Healthcare Conference?

Zymeworks management will hold one-on-one meetings on November 17–19, 2025 in London, UK.

How can investors access Zymeworks (ZYME) conference meetings or materials?

The company typically arranges one-on-one investor meetings and may post any presentation materials on its investor relations website after the events.

Will Zymeworks (ZYME) provide clinical updates at the November 2025 conferences?

Management may discuss clinical progress in one-on-one meetings, but no public clinical readouts or formal presentation were announced.

Are Zymeworks (ZYME) conference meetings open to retail investors?

One-on-one meetings are generally arranged for institutional investors and analysts; retail investors should check the investor relations page for any public webcasts or materials.

Which topics is Zymeworks (ZYME) likely to cover with investors at the November 2025 conferences?

Expect discussion of the company's clinical-stage pipeline, development timelines, and corporate strategy, consistent with typical investor meetings.